急性膵炎におけるピルフェニドンの安全性と忍容性
中等度から重度の急性膵炎が予測される患者における治療としてのピルフェニドンの評価
The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis. Pirfenidone is currently approved by FDA for the treatment of idiopathic pulmonary fibrosis. Now, over 5 years of data has accumulated demonstrating safety of its use in humans. The investigators' preclinical data suggest that pirfenidone is very effective in reducing the severity of acute pancreatitis in animal models. Following are the objectives of the proposed clinical trial:
Primary Objective:
- To evaluate the safety and tolerability of pirfenidone, compared to placebo, in patients predicted to have moderately severe or severe AP.
- To evaluate the efficacy of pirfenidone in reducing the laboratory markers of inflammation and improving patient reported outcome measures.
Secondary Objective:
- To evaluate the efficacy of pirfenidone in reducing the severity of acute pancreatitis, as measured by well-defined endpoints.
調査の概要
詳細な説明
The study is a Randomized Pilot clinical trial evaluating safety and tolerability of pirfenidone in patients with predicted moderately severe to severe acute pancreatitis. There are built in secondary end-points for efficacy. The patients with acute pancreatitis, who present within 48h of establishment of the diagnosis, will be screened for exclusion and inclusion criteria and consented for the clinical trial. Patients with be randomized into placebo or pirfenidone arm and followed daily in-person, while in hospital, and by telephone once discharged from the hospital (weekly for 4 weeks, then monthly for up to 6 months) for study end points.
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- UAB
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients 18 - 85 years of age
-
Admitted to hospital for AP, defined by at least 2 of the following 3:
- amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values
- characteristic cross-sectional imaging
- typical upper abdominal pain- acute onset of a persistent, severe, epigastric pain often radiating to the back
-
Patients identified, approached, and consented to administer study medication or placebo within 48 hours of diagnosis of AP.
-
Predicted to have MSAP or SAP by presence of one or more of the following criteria
- APACHE II ≥ 8
- Modified Glasgow or Imrie score ≥ 3
- CRP > 150 mg/dL
- PASS score > 140 at or within 48 hrs. of admission
- CT or MRI imaging suggesting pancreatic and/or peri-pancreatic necrosis
Exclusion Criteria:
- Age < 18 or > 85 years
- Body weight > 200 kg
- Presentation to the medical attention > 48 h after diagnosis of AP
- Inability to recruit, randomize and start the allocated treatment within 48h of start of pain
- Ongoing AP or diagnosis of AP in previous 30 days
- Chronic pancreatitis
- Known hypersensitivity to pirfenidone
- AST/ALT ≥ 2 times the upper normal limit.
- Alkaline phosphatase ≥ 2 times the upper normal limit
- Bilirubin higher than upper normal limit
- Moderate to severe heart failure and/or coronary heart disease (New York Heart Association (NYHA) Functional Class III/IV)
- On home oxygen or home mechanical ventilation
- Advanced liver disease
- Paralytic ileus or significant nausea and vomiting
- Chronic Diarrhea
- Immunosuppressive disorder or on immunosuppressive medications
- Active or advanced malignancy
- Known cancer that is end-stage with ongoing palliative care or for which palliative care is appropriate
- Known established infection prior to the onset of acute pancreatitis
- Known history of infective hepatitis
- Known live vaccines or therapeutic infectious agents within one month of admission
- Known pregnancy or lactation at the time of admission
- Ongoing photosensitivity and rash
- Women of childbearing potential who are not on oral or injectable contraceptives or IUDs and do not consent to practice abstinence for period of 4 weeks.
- Known to be currently participating in a trial testing any investigational medicinal product or participation in a clinical study involving a medicinal product in the last three months
- Alcohol or substance abuse in the past 2 years
- Family or personal history of long QT syndrome ( > 500 msec)
- Medications like fluvoxamine or sildanefil
- Significant photosensitivity or new rash
- Renal disease with GFR < 30
- Any condition other than above that, in the opinion of the investigator, is likely to result in the death of the patient within the next 2 years
- Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:プラセボ
|
The placebo tablets will be an exact replica of the pirfenidone tablet. |
|
実験的:ピルフェニドン治療
|
Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Development of Anticipated or Un-anticipated Adverse Events (Class 3 or 4)
時間枠:6 months
|
Development of anticipated or un-anticipated adverse events (class 3 or 4) |
6 months
|
|
Percentage of Patients Starting and Completion of the Planned Drug Treatment
時間枠:7 days
|
percentage of patients starting and completion of the planned drug treatment |
7 days
|
|
Changes in C-reactive Protein (CRP), TNF-α, Interleukin (IL)-6, IL-8 and IL-10 Levels
時間枠:7 days
|
Compared to base line |
7 days
|
|
Percentage of Patients Having Decrease in PAN-PROMISE Score by at Least 10 Points at 72h After Initiation of the Drug
時間枠:3 days
|
Measurement of PAN-PROMISE score |
3 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cumulative PAN-PROMISE Score
時間枠:7 days
|
total of the PAN-PROMISE over 7 days |
7 days
|
|
Cumulative PASS Score
時間枠:duration of admission
|
total of PASS score during admission |
duration of admission
|
|
PASS Score at the Time of Discharge
時間枠:duration of admission
|
PASS score measurement |
duration of admission
|
|
Composition Outcome
時間枠:6 months
|
total of development of new or worsening pancreatic or peri-pancreatic necrosis, death or major infection |
6 months
|
|
Readmission and/or ER Visits
時間枠:within 30 days and within 6 months
|
within 30 days and within 6 months
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Palathingal Bava E, George J, Tarique M, Iyer S, Sahay P, Gomez Aguilar B, Edwards DB, Giri B, Sethi V, Jain T, Sharma P, Vaish U, C Jacob HK, Ferrantella A, Maynard CL, Saluja AK, Dawra RK, Dudeja V. Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models. JCI Insight. 2022 Jan 25;7(2):e141108. doi: 10.1172/jci.insight.141108.
- Bava EP, Jain T, Al-Obaidi M, Evans Z, Doto D, Vege SS, Dudeja V. Safety, tolerability and therapeutic efficacy of anti-inflammatory drug pirfenidone in acute pancreatitis patients: Protocol for a randomized pilot clinical trial. Pancreatology. 2025 Mar;25(2):214-220. doi: 10.1016/j.pan.2025.01.004. Epub 2025 Jan 13.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。